Li X L, Yu Y, Zong X Y
Department of Breast Surgery, Shanghai Jiao Tong University affiliated Shanghai Sixth People's Hospital, Shanghai 200233, China.
Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Zhonghua Zhong Liu Za Zhi. 2019 Apr 23;41(4):246-250. doi: 10.3760/cma.j.issn.0253-3766.2019.04.002.
Gonadotropin-releasing-hormone analogues (GnRHa) are widely used in the treatment of premenopausal breast cancer. The anti-tumor effect of GnRHa is similar to that of surgical castration or chemotherapy, through reversibly inhibiting ovarian function and downregulating the estrogen level in premenopausal female. At the same time, GnRHa can protect the ovarian function, avoiding premature ovarian failure. Also GnRHa can reduce the breast density and endometrial thickness, as a result of which GnRHa may be used to prevent breast cancer in the higher risk population and promote quality of life in breast cancer patients. We here review the clinical roles and research progress of GnRHa in breast cancer.